RxDoctor Payments Data

Carey Pulido

Family · Bend, ORNPI 1811380157

Payments from drug & device makers

$1,318in general payments, 2019–2025

Across 35 payments — averaging $37.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$350
  • Bayer$174
  • Abbott$160
  • Novo Nordisk$140
  • Medtronic$93
  • Regeneron Healthcare Solutions, Inc.$92
  • plus $309 from 5 others

What the payments were for

  • Food & beverage$1,29798%
  • Education$202%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,318 in reported general payments places this provider in the 85th percentile of 1,130 family providers in Oregon.

See all family providers in Oregon

Medicare billing

Part B allowed, 2024
$62,374
Medicare patients
371
Services billed
1,827

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin138$175,086
TrulicityDulaglutide77$129,539
OzempicSemaglutide68$117,009
MounjaroTirzepatide42$61,141
Tresiba Flextouch U-200Insulin Degludec21$30,049
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog22$16,730
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog22$12,366
Lantus SolostarInsulin Glargine,hum.Rec.Anlog76$9,503
Tresiba Flextouch U-100Insulin Degludec15$8,353
Novolog FlexpenInsulin Aspart36$6,786
Insulin Degludec Pen (U-200)Insulin Degludec14$3,627
SynthroidLevothyroxine Sodium27$2,190
Metformin Hcl ErMetformin Hcl141$1,982
Nano 2nd Gen Pen NeedlePen Needle, Diabetic18$1,127
Levothyroxine Sodium116$1,110

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$140$117,00968 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,130 family providers in Oregon.

Other family in Bend

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →